How did Bal Pharma's Q4 profit compare to the previous year?

The company's standalone net profit dropped 34% to ₹3.70 crore, compared to ₹5.61 crore in the same quarter of the prior year.

What corporate actions did the board approve?

The board formally approved a preferential issue of 10,00,000 warrants to promoters and recommended a dividend of ₹1 per share.

Is there any surprise in these results?

No. The results are routine for an annual announcement and align with market expectations for the company.

Earnings · Pharmaceuticals · Micro cap

Bal Pharma profit slips 34% as board approves promoter warrants

The pharmaceutical company reported a Q4 net profit of ₹3.70 crore, down from ₹5.61 crore in the same period last year.

— 1 earlier story on Bal Pharma Ltd. →

BALPHARMA 27 May 2026 · 6:48 PM IST Verify on BSE · NSE

Mkt cap₹154 cr

P/E18.90×

ROE9.32%

Debt / eq.1.94

Div yld1.30%

₹3.70 cr Standalone net profit for the quarter ended March 31, 2026.

What's new

Q4 net profit fell 34% to ₹3.70 crore from ₹5.61 crore a year ago.
The board approved a preferential issue of 10,00,000 warrants to promoters.
Directors recommended a dividend of ₹1 per share.

Why this matters

The earnings release shows a contraction in profitability despite marginal revenue growth. The formal approval of promoter warrants and the dividend recommendation are standard corporate actions for a company of this size.

What we're watching

Whether the preferential issue of warrants leads to further capital infusion.
The company's ability to improve margins in the coming quarters.
Shareholder response to the proposed dividend.

The full read

Bal Pharma reported a 34% decline in standalone net profit for the quarter ended March 31, 2026, falling to ₹3.70 crore from ₹5.61 crore in the same period last year. While revenue saw marginal growth, the bottom line contraction reflects a challenging quarter for the ₹148 crore market cap firm. Alongside the financial results, the board formally approved the previously proposed preferential issue of 10,00,000 warrants to promoters. Directors also recommended a dividend of ₹1 per share. These developments are routine for the company's annual results cycle and do not deviate from market expectations.

Questions answered

How did Bal Pharma's Q4 profit compare to the previous year?: The company's standalone net profit dropped 34% to ₹3.70 crore, compared to ₹5.61 crore in the same quarter of the prior year.
What corporate actions did the board approve?: The board formally approved a preferential issue of 10,00,000 warrants to promoters and recommended a dividend of ₹1 per share.
Is there any surprise in these results?: No. The results are routine for an annual announcement and align with market expectations for the company.

Mentioned: Bal Pharma · 10,00,000 warrants · March 31, 2026

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on BALPHARMA →

27 May 2026 · 6:48 PM IST Bal Pharma profit slips 34% as board approves promoter warrants
today Bal Pharma profit drops 34% as board approves promoter warrant issue